92-61-5Relevant articles and documents
-
Braymer et al.
, p. 163 (1960)
-
Coumarins from Astragalus asper
Guzhva
, p. 767 - 768 (2008)
-
COUMARIN COMPOSITION OF Haplophyllum bungei
Abyshev, A. Z.,Gashimov, N. F.
, p. 615 - 616 (1982)
-
A COUMARIN GLUCOSIDE FROM XEROMPHIS OBOVATA
Sibanda, S.,Ndengu, B.,Multari, G.,Pompi, V.,Galeffi, C.
, p. 1550 - 1552 (1989)
From root bark of Xeromphis obovata three coumarins have been isolated: scopoletin, its 7-β-D-glucopyranoside (scopolin) and the new β-D-apiosyl-(1" -> 6)-β-D-glucopyranoside of scopoletin, named xeroboside.Also two iridoids, deacetylasperulosidic acid methyl ester and gardenoside, have been isolated and identified as the corresponding acetyl derivetives. Key Word Index-Xeromphis obovata; Rubiaceae; coumarins; iridoids; xeroboside.
COUMARINS OF Ptarmica bisserata
Davidyats, E. S.
, p. 233 (1982)
-
Novel NO-releasing scopoletin derivatives induce cell death via mitochondrial apoptosis pathway and cell cycle arrest
Chen, Cheng,Chen, Li,Lei, Zhichao,Li, Na,Shi, Zhixian,Sun, Jianbo,Wang, Yujin
, (2020/05/19)
A series of phenylsulfonyfuroxan-based NO-releasing scopoletin derivatives were designed and synthesized in the study. All target compounds showed significantly improved antiproliferative activity against four cancer cell lines (MDA-MB-231, MCF-7, HepG2 and A459) and lower cytotoxicity toward normal liver LO2 cells. Derivative 47 concentration-dependently inhibited the colony formation of MDA-MB-231 cells. NO-releasing assessment indicated that the intracellular NO level was almost positively correlated with the antiproliferative ability. Compound 47, which released the highest amounts of NO, showed the best potency (IC50 = 1.23 μM) against MDA-MB-231 cells. Mechanism research revealed for the first time that 47 blocked the proliferation of MDA-MB-231 cells by activating mitochondrial apoptosis pathway and arresting cell cycle at G2/M phase. Taken together, as a novel scopoletin derivative, 47 exhibited excellent inhibitory effects against malignant cancer cells and lower toxicity on normal cells. Thus, an in-depth evaluation of 47 to explore its complete therapeutic potential for cancer treatment is warranted.
Preparation method of scopoletin
-
Paragraph 0048-0052, (2019/10/04)
The invention discloses a preparation method of scopoletin, which comprises the following steps: 1) with 2,4-dihydroxy-5-methoxybenzaldehyde as an initial raw material, adding a solvent and a catalyst, adding a malonic acid compound within a reaction temperature range of 0-300 DEG C, and carrying out a heat preservation reaction for 2-10 hours to obtain a reaction solution, the usage amount of the malonic acid compound being 1-10 equivalents; 2) cooling the reaction solution at a cooling temperature of -10 DEG C to 35 DEG C, wherein a large amount of solids is separated after the reaction solution is cooled, and carrying out reduced pressure suction filtration on the reaction solution from which the large amount of solids are separated out to obtain a crude product of the scopoletin and filtrate; and 3) recrystallizing the crude product of the scopoletin with ethyl acetate to obtain a pure product of the scopoletin. The method has the advantages of high yield, low cost and low pollution.
